Innovative liquid biopsy with only one urine sample is more than 90% accurate in predicting prostate cancer

Recently, the data released by miR Scientific at the annual meeting of the American Urological Association (AUA) showed that its technology of using urine to detect prostate cancer can accurately detect prostate cancer at the molecular level and classify its risk
.

This prostate cancer detection technology, called miR Sentinel, has been certified by the FDA as a breakthrough medical device.
It is a non-invasive molecular test based on the analysis of small non-coding RNA (sncRNA) in exosomes in urine
.

Image source: miR Scientific's official website

When comparing the results of miR Sentinel detection technology with systematic needle biopsy among men who were initially suspected of prostate cancer, the study showed that the consistency of the two screening and detection methods in the classification of clinically significant cancer was 93%
.

(The original text has been deleted)

Reference materials:

[1] miR Scientific Presents Groundbreaking Data on the Exceptional Accuracy of its Prostate Cancer Liquid-Biopsy Test.